trending Market Intelligence /marketintelligence/en/news-insights/trending/K2aM9UdGj1GzQC3KsQei1w2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Allergan settling patent litigation with InnoPharma over dry eye drug Restasis

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Allergan settling patent litigation with InnoPharma over dry eye drug Restasis

Allergan plc reached an agreement to resolve its patent litigation with Innopharma Inc. related to six patents on dry eye drug Restasis.

The patents are listed in the Orange Book and expire Aug. 27, 2024.

Under the settlement, all InnoPharma Hatch-Waxman litigation related to Restasis patents will be dismissed. Allergan will also grant InnoPharma licenses to market a generic version of Restasis in the U.S., starting Feb. 24, 2024, or earlier under certain circumstances.

In addition, under certain circumstances, the company will supply and authorize InnoPharma to launch an authorized generic version of Restasis on Aug. 28, 2024.

Additional details regarding the settlement were not disclosed.